Αρχειοθήκη ιστολογίου

Τρίτη 10 Οκτωβρίου 2017

High frequency of brain metastases after adjuvant therapy for high-risk melanoma

Abstract

The incidence of CNS progression in patients with high-risk regional melanoma (stages IIIAN2a-IIIC) is not well characterized. Data from the S0008 trial provided an opportunity to examine the role of CNS progression in treatment failure and survival. All patients were surgically staged. Following wide excision and full regional lymphadenectomy, patients were randomized to receive adjuvant biochemotherapy (BCT) or high-dose interferon alfa-2B (HDI). CNS progression was retrospectively identified from data forms. Survival was measured from date of CNS progression. A total of 402 eligible patients were included in the analysis (BCT: 199, HDI: 203). Median follow-up (if alive) was over 7 years (range: 1 month to 11 years). The site of initial progression was identifiable in 80% of relapsing patients. CNS progression was a component of systemic melanoma relapse in 59/402 patients (15% overall). In 34/402 patients (9%) CNS progression represented the initial site of treatment failure. CNS progression was a component of initial progression in 27% of all patients whose melanoma relapsed (59/221). The risk of CNS progression was highest within 3 years of randomization. The difference in CNS progression rates between treatment arms was not significant (BCT = 25, HDI = 34, = 0.24). Lymph node macrometastases strongly associated with CNS progression (= 0.001), while ulceration and head and neck primaries were not significant predictors. This retrospective analysis of the S0008 trial identified a high brain metastasis rate (15%) in regionally advanced melanoma patients. Further studies are needed to establish whether screening plus earlier treatment would improve survival following CNS progression.

Thumbnail image of graphical abstract

The frequency of brain metastases developing in advanced regional melanoma (Stage IIIB and C) remains poorly defined. We performed a retrospective analysis of a large patient sample that were staged and managed using contemporary techniques from the intergroup trial SWOG 0008 to provide an estimate of the risk of CNS relapse. Difference between treatment arms was not expected. This data provides a basis for design of future studies for surveillance and treatment of early brain metastases.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2yddpNK

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου